中文簡(jiǎn)介

《國(guó)際藥學(xué)雜志》提供了一種出版創(chuàng)新論文、評(píng)論、小型評(píng)論、簡(jiǎn)短交流和筆記的媒介，涉及物理、化學(xué)、生物、微生物和工程研究，涉及藥物在體內(nèi)和體外傳遞系統(tǒng)的概念、設(shè)計(jì)、生產(chǎn)、特性和評(píng)價(jià)?！八幬铩倍x為任何治療或診斷實(shí)體，包括寡核苷酸、基因構(gòu)建物和放射性藥物。特別感興趣的領(lǐng)域包括:物理藥學(xué);高分子化學(xué)和物理化學(xué)在制藥中的應(yīng)用賦形劑的功能和特性;生物藥劑學(xué);吸收機(jī)制;膜的功能和運(yùn)輸;新穎的送貨路線和方式;反應(yīng)性傳遞系統(tǒng)、反饋和控制機(jī)制，包括生物傳感器;細(xì)胞和分子生物學(xué)在藥物傳遞中的應(yīng)用前藥設(shè)計(jì);輔料(carrier-ligand互動(dòng));生物技術(shù)(蛋白質(zhì)和肽傳遞)。編輯政策出版的首要標(biāo)準(zhǔn)是原創(chuàng)性、高科學(xué)質(zhì)量和對(duì)多學(xué)科讀者的興趣。未經(jīng)實(shí)驗(yàn)細(xì)節(jié)充分證實(shí)的論文將不予發(fā)表。任何技術(shù)問(wèn)題都將提交給作者，盡管編輯保留在不改變技術(shù)內(nèi)容的情況下修改文本的權(quán)利。以多重作者身份提交的稿件將在假定所有列出的作者都同意提交的情況下進(jìn)行審查，并且最終稿件的副本已得到所有作者的批準(zhǔn)，并已由進(jìn)行工作的實(shí)驗(yàn)室的主管當(dāng)局默認(rèn)或明確地批準(zhǔn)。未經(jīng)編輯出版者同意，稿件不得在其他地方以相同的形式、相同的文字或者其他文字發(fā)表。在提交論文發(fā)表時(shí)，作者必須在附信中說(shuō)明他們的工作或研究方法所體現(xiàn)的新穎性。常規(guī)的生物等效性研究不太可能受到青睞。本署將不會(huì)發(fā)表任何論文，不完全披露所使用的配方的性質(zhì)或?qū)Ξa(chǎn)品、藥物或輔料的性能至關(guān)重要的材料的詳情。結(jié)果可預(yù)測(cè)的工作，例如在環(huán)糊精中加入另一種藥物以產(chǎn)生更強(qiáng)的溶解性，將不會(huì)發(fā)表，除非它對(duì)基本原理提供了新的見(jiàn)解。

投稿網(wǎng)址：http://ees.elsevier.com/ijp/

英文簡(jiǎn)介

The International Journal of Pharmaceutics provides a medium for the publication of innovative papers, reviews, mini-reviews, short communications and notes dealing with physical, chemical, biological, microbiological and engineering studies related to the conception, design, production, characterisation and evaluation of drug delivery systems in vitro and in vivo. "Drug" is defined as any therapeutic or diagnostic entity, including oligonucleotides, gene constructs and radiopharmaceuticals. Areas of particular interest include: physical pharmacy; polymer chemistry and physical chemistry as applied to pharmaceutics; excipient function and characterisation; biopharmaceutics; absorption mechanisms; membrane function and transport; novel routes and modes of delivery; responsive delivery systems, feedback and control mechanisms including biosensors; applications of cell and molecular biology to drug delivery; prodrug design; bioadhesion (carrier-ligand interactions); and biotechnology (protein and peptide delivery). Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher. Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.